US Patent Issued to Arrowhead Pharmaceuticals on Jan. 27 for "RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use" (California, New Jersey Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,728, issued on Jan. 27, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use" was invented by Zhen Li (Westfield, N.J.), Rui Zhu (San Diego) and Shawn A Morales (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit 17Beta-hydroxysteroid dehydrogenase type 13 (HSD17B13 or 17Beta-HSD13) gene expression. Also disclosed are pharmaceutical compositions that include HSD17B13 RNAi agents and methods of use thereof. The HSD17B13 RN...